CoChat
Sign Up
Cited by 52

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases

Afrin, Lawrence B., Pöhlau, Dieter, Raithel, Martin, Haenisch, Britta, Dumoulin, Franz L., Homann, Juergen, Mauer, Uwe M., Harzer, Sabrina, Molderings, Gerhard J.·2015·Brain, Behavior, and Immunity
DOI 10.1016/j.bbi.2015.07.002
Open this paper in CoChat — free account

Abstract

Neurologists and psychiatrists frequently encounter patients whose central and/or peripheral neurologic and/or psychiatric symptoms (NPS) are accompanied by other symptoms for which investigation finds no unifying cause and for which empiric therapy often provides little to no benefit. Systemic mast cell activation disease (MCAD) has rarely been considered in the differential diagnosis in such situations. Traditionally, MCAD has been considered as just one rare (neoplastic) disease, mastocytosis, generally focusing on the mast cell (MC) mediators tryptase and histamine and the suggestive, blatant symptoms of flushing and anaphylaxis. Recently another form of MCAD, MC activation syndrome (MC), has been recognized, featuring inappropriate MC activation with little to no neoplasia and likely much more heterogeneously clonal and far more prevalent than mastocytosis. There also has developed greater appreciation for the truly very large menagerie of MC mediators and their complex patterns of release, engendering complex, nebulous presentations of chronic and acute illness best characterized as multisystem polymorbidity of generally inflammatory ± allergic themes--including very wide arrays of central and peripheral NPS. Significantly helpful treatment--including for neuropsychiatric issues--usually can be identified once MCAD is accurately diagnosed. We describe MCAD's pathogenesis, presentation (focusing on NPS), and therapy, especially vis-à-vis neuropsychotropes. Since MCAD pat…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2015.07.002

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 49

  1. Afrin, L., 2013. Presentation, diagnosis, and management of mast cell activation syndrome. In: Mast Cells: Phenotypic Features, Biological Functions, and Role in Immunity. Nova Science Publishers, Happauge, NY, pp. 155–231. Available at: <https://www.novapublishers.com/catalog/product_info.php?products_id=42603> (accessed 14.06.15).
  2. Alysandratos, 2012, Neurotensin and CRH interactions augment human mast cell activation, PLoS One, 7, e48934, 10.1371/journal.pone.0048934 · DOI
  3. Ashina, 2004, Headache in systemic mastocytosis: a case report with pathophysiological considerations, Cephalalgia, 25, 314, 10.1111/j.1468-2982.2004.00852.x · DOI
  4. Barbara, 2006, Functional gastrointestinal disorders and mast cells: implications for therapy, Neurogastroenterol. Motil., 18, 6, 10.1111/j.1365-2982.2005.00685.x · DOI
  5. Bornstein, 2008, Involvement of heparanase in the pathogenesis of localized vulvodynia, Int. J. Gynecol. Pathol., 27, 136, 10.1097/pgp.0b013e318140021b · DOI
  6. Calvo, 2013, The role of melatonin in the cells of the innate immunity: a review, J. Pineal Res., 55, 103, 10.1111/jpi.12075 · DOI
  7. Chatterjea, 2015, Mast cells: versatile gatekeepers of pain, Mol. Immunol., 63, 38, 10.1016/j.molimm.2014.03.001 · DOI · Paper page
  8. Church, 1980, Inhibition of histamine release from human lung in vitro by antihistamines and related drugs, Br. J. Pharmacol., 69, 663, 10.1111/j.1476-5381.1980.tb07919.x · DOI
  9. Demir, 2013, Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis, PLoS One, 8, e60529, 10.1371/journal.pone.0060529 · DOI
  10. Dere, 2010, Neuronal histamine and the interplay of memory, reinforcement and emotions, Behav. Brain Res., 215, 209, 10.1016/j.bbr.2009.12.045 · DOI
  11. Dubayle, 2005, Differential effects of two analgesic drugs, morphine chlorhydrate and acetylsalicylic acid, on thalamic mast cell numbers in rat, J. Neuroimmunol., 169, 106, 10.1016/j.jneuroim.2005.08.008 · DOI
  12. Frieling, 2011, Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome, Z. Gastroenterol., 49, 191, 10.1055/s-0029-1245707 · DOI
  13. Gianlorenço, 2012, Emotional memory consolidation impairment induced by histamine is mediated by H1 but not H2 receptors, Brain Res. Bull., 89, 197, 10.1016/j.brainresbull.2012.09.003 · DOI
  14. Goldschmidt, 1985, Rat brain mast cells: contribution to brain histamine levels, J. Neurochem., 44, 1943, 10.1111/j.1471-4159.1985.tb07191.x · DOI
  15. Gri, 2012, Mast cell: an emerging partner in immune interaction, Front. Immunol., 3, 120, 10.3389/fimmu.2012.00120 · DOI
  16. Grotenhermen, 2012, The therapeutic potential of cannabis and cannabinoids, Dtsch. Arztebl. Int., 109, 495
  17. Haenisch, 2012, Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics, Immunology, 137, 197, 10.1111/j.1365-2567.2012.03627.x · DOI · Paper page
  18. Hermine, 2008, Case–control cohort study of patients’ perceptions of disability in mastocytosis, PLoS One, 3, e2266, 10.1371/journal.pone.0002266 · DOI
  19. Hugel, 2003, Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain, J. Pain Symptom Manage., 26, 1073, 10.1016/j.jpainsymman.2003.09.005 · DOI
  20. Janiszewski, 1994, Picomolar doses of substance P trigger electrical responses in mast cells without degranulation, Am. J. Physiol., 267, C138, 10.1152/ajpcell.1994.267.1.C138 · DOI
  21. Kawabata, 2011, Prostaglandin E2 and pain – an update, Biol. Pharm. Bull., 34, 1170, 10.1248/bpb.34.1170 · DOI
  22. Khalil, 2007, Brain mast cell relationship to neurovasculature during development, Brain Res., 1171, 18, 10.1016/j.brainres.2007.07.034 · DOI
  23. Kovacs, 2006, Mast cells modulate maintained neuronal activity in the thalamus in vivo, J. Neuroimmunol., 171, 1, 10.1016/j.jneuroim.2005.07.026 · DOI
  24. Kulka, 2008, Neuropeptides activate human mast cell degranulation and chemokine production, Immunology, 123, 398, 10.1111/j.1365-2567.2007.02705.x · DOI
  25. Kushnir-Sukhov, 2008, Clinical correlates of blood serotonin levels in patients with mastocytosis, Eur. J. Clin. Invest., 38, 953, 10.1111/j.1365-2362.2008.02047.x · DOI · Paper page
  26. Lavich, 2003, Combined action of vasoactive amines and bradykinin mediates allergen-evoked thermal hyperalgesia in rats, Eur. J. Pharmacol., 462, 185, 10.1016/S0014-2999(02)02947-3 · DOI
  27. Levy, 2012, Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity, Brain Behav. Immun., 26, 311, 10.1016/j.bbi.2011.09.016 · DOI
  28. Lucas, 2006, Fibromyalgia – new concepts of pathogenesis and treatment, Int. J. Immunopathol. Pharmacol., 19, 5, 10.1177/205873920601900102 · DOI
  29. Lundequist, 2011, Biological implications of preformed mast cell mediators, Cell Mol Life Sci., 68, 965, 10.1007/s00018-010-0587-0 · DOI
  30. Maintz, 2011, Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis, Allergy, 66, 862, 10.1111/j.1398-9995.2011.02550.x · DOI
  31. Maldonado, 2010, Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation, Pharmacol. Res., 62, 282, 10.1016/j.phrs.2009.11.014 · DOI
  32. Maślińska, 2005, Post-infectional distribution and phenotype of mast cells penetrating human brains, Inflamm. Res., 54, S15, 10.1007/s00011-004-0406-x · DOI
  33. McAfoose, 2009, Evidence for a cytokine model of cognitive function, Neurosci. Biobehav. Rev., 33, 355, 10.1016/j.neubiorev.2008.10.005 · DOI · Paper page
  34. Molderings, 2015, The genetic basis of mast cell activation disease – looking through a glass darkly, Crit. Rev. Oncol. Hematol., 93, 75, 10.1016/j.critrevonc.2014.09.001 · DOI · Paper page
  35. Molderings, 2011, Omalizumab treatment of systemic mast cell activation disease: experiences from four cases, Intern. Med., 50, 611, 10.2169/internalmedicine.50.4640 · DOI
  36. Nautiyal, 2009, Mast cells are necessary for the hypothermic response to LPS-induced sepsis, Am. J. Physiol. Regul. Integr. Comp. Physiol., 296, R595, 10.1152/ajpregu.90888.2008 · DOI
  37. Nelissen, 2013, The role of mast cells in neuroinflammation, Acta Neuropathol., 125, 637, 10.1007/s00401-013-1092-y · DOI
  38. Ng, 2010, The role of mast cells in wound healing, Int. Wound J., 7, 55, 10.1111/j.1742-481X.2009.00651.x · DOI
  39. Okuse, 2007, Pain signalling pathways: from cytokines to ion channels, Int. J. Biochem. Cell. Biol., 39, 490, 10.1016/j.biocel.2006.11.016 · DOI
  40. Pang, 1996, Definitive characterization of rat hypothalamic mast cells, Neuroscience, 73, 889, 10.1016/0306-4522(95)00606-0 · DOI
  41. Peng, 2013, Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis, Blood, 122, 1779, 10.1182/blood-2012-12-469882 · DOI
  42. Poglio, 2010, Adipose tissue as a dedicated reservoir of functional mast cell progenitors, Stem Cells, 28, 2065, 10.1002/stem.523 · DOI · Paper page
  43. Porzionato, 2004, The distribution of mast cells in the human area postrema, J. Anat., 204, 141, 10.1111/j.1469-7580.2004.00256.x · DOI
  44. Shanas, 1998, Brain mast cells lack the c-kit receptor: immunocytochemical evidence, J. Neuroimmunol., 90, 207, 10.1016/S0165-5728(98)00137-4 · DOI
  45. Silver, 2013, Mast cells on the mind: new insights and opportunities, Trends Neurosci., 36, 513, 10.1016/j.tins.2013.06.001 · DOI
  46. Smith, 2011, Neurologic symptoms and diagnosis in adults with mast cell disease, Clin. Neurol. Neurosurg., 113, 570, 10.1016/j.clineuro.2011.05.002 · DOI
  47. Theoharides, 2007, Differential release of mast cell mediators and the pathogenesis of inflammation, Immunol. Rev., 217, 65, 10.1111/j.1600-065X.2007.00519.x · DOI
  48. Turygin, 2005, Characteristics of mast cells in the choroid plexus of the ventricles of the human brain in aging, Neurosci. Behav. Physiol., 35, 909, 10.1007/s11055-005-0144-8 · DOI
  49. Zarrindast, 2008, Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats, Eur. J. Pharmacol., 583, 108, 10.1016/j.ejphar.2008.01.003 · DOI

Cited by

Sorted by citations

See all 52

Metadata

Authors
Afrin, L. B., Pöhlau, D., Raithel, M., Haenisch, B., Dumoulin, F. L., Homann, J., Mauer, U. M., Harzer, S., & Molderings, G. J.
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2015-11
Volume
50
Pages
314-321
ISSN
0889-1591
DOI
10.1016/j.bbi.2015.07.002
Cited by
52
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review